港股异动 | 绿叶制药(02186)高开逾3% 治疗帕金森病长效微球制剂金悠平®在华获批上市
绿叶制药(02186)高开逾3%，截至发稿，涨3.15%，报2.95港元，成交额99.56万港元。
消息面上，绿叶制药宣布，其自主研发的创新微球制剂——金悠平®（注射用罗替高汀微球），作为纳入优先审评审批程序的品种，已获得国家药监局的上市批准，用于帕金森病的治疗。据悉，金悠平®是全球首个治疗帕金森病的长效缓释微球制剂，也是目前更符合“持续多巴胺能刺激（CDS）”理念的周制剂。
天风证券此前指出，考虑到公司新产品优势突出，将有多款药物上市，核心业务主要品种市场空间大，看好公司发展。2024年有望迎来多款产品获批上市，包括芦比替定、羟考酮纳洛酮、罗替高汀微球、帕利哌酮微晶、博洛加（地舒单抗）。
Reprinted from 引领外汇网，the copyright all reserved by the original author.
Disclaimer: The content above represents only the views of the author or guest. It does not represent any views or positions of FOLLOWME and does not mean that FOLLOWME agrees with its statement or description, nor does it constitute any investment advice. For all actions taken by visitors based on information provided by the FOLLOWME community, the community does not assume any form of liability unless otherwise expressly promised in writing.
FOLLOWME Trading Community Website: https://www.followme.com
Hot
No comment on record. Start new comment.